COMMUNIQUÉS West-GlobeNewswire

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom
14/11/2025
TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
14/11/2025
INSIDE INFORMATION REGULATED INFORMATION Correction and Replacement Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments [...]
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
14/11/2025
Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued earlier this morning [...]
Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress
13/11/2025
Conference call today, November 13, 2025, at 4:30 PM ET SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2025 [...]
Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
13/11/2025
~ Q3 2025 Total Net Product Sales of $12.5 Million, 79% Year Over Year Growth ~ ~ Q3 2025 Positive Cash Flow from Operations, Cash Position Grew to $22 Million ~ ~ Japan Clinical Trial (STS-J01) Preliminary Results [...]
Amneal Receives U.S. FDA Approval for Iohexol Injection
13/11/2025
First-to-market complex injectable with expected launch in Q1 2026 BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. [...]
Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update
13/11/2025
DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product Revenue Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued Enrollment [...]
BioStem Technologies Reports Third Quarter 2025 Financial Results
13/11/2025
POMPANO BEACH, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for [...]
Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights
13/11/2025
Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD [...]
STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
13/11/2025
HORSHAM, Penn., Nov. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
PacBio to Present at Upcoming Investor Conferences
13/11/2025
MENLO PARK, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the [...]
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
13/11/2025
Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its potential as a best-in- [...]
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
13/11/2025
Results from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) presented as IDWeek late-breaker in October 2025 Spero’s development partner, GSK, plans to submit data from the [...]
CapsoVision Reports Third Quarter 2025 Financial Results
13/11/2025
SARATOGA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported [...]
ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety
13/11/2025
Efficacy data remain consistent with prior disclosure and continue to demonstrate broad and deep PSA responses, with 55% PSA50 response rate and 20% PSA90 response rate Rapid and deep ctDNA reductions were observed in [...]
Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis
13/11/2025
SOUTH JORDAN, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services (“ [...]
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
13/11/2025
Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approval Company is in [...]
BioSyent Schedules Q3 and YTD 2025 Earnings Release for November 20, 2025
13/11/2025
MISSISSAUGA, Ontario, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and nine months ended September 30, 2025 on [...]
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
13/11/2025
100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 patients [...]

Pages